World Roche’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study April 17, 2023
Business Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc. April 16, 2023
World Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection versus KEYTRUDA April 16, 2023
